Pediatric Zylet Safety and Efficacy Study
A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum)
Chalazion|Hordeolum
DRUG: loteprednol etabonate/tobramycin opthalmic suspension|DRUG: vehicle
Treatment Emergent Adverse Events, Study eye - Safety Population, At all visits 1,2,3, day 1, day 8, day 15
Investigators Global Assessment of the Clinical Condition, The efficacy endpoints for this study consisted of reduction of inflammation as measured by the IGA of the clinical condition. Changes in clinical condition measured as improved, unchanged or worsened., Visit 3, day 8|Assessment of Ocular Signs in the Study Eye - Visit 1, Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe., Visit 1 (day 1)|Assessment of Ocular Signs in the Study Eye - Visit 2, Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe., Visit 2 (day 8)|Assessment of Ocular Signs in the Study Eye - Visit 3, Lid edema, lid erythema, palpebral conjunctival injection, meibomium plugging measured on a scale of 0-4 none, minimal, mild, moderate, severe., Visit 3 (day 15)
A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum)